Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline.

Koyfman SA, Ismaila N, Crook D, D'Cruz A, Rodriguez CP, Sher DJ, Silbermins D, Sturgis EM, Tsue TT, Weiss J, Yom SS, Holsinger FC.

J Clin Oncol. 2019 Feb 27:JCO1801921. doi: 10.1200/JCO.18.01921. [Epub ahead of print]

PMID:
30811281
2.

Postoperative Combined Modality Treatment in High Risk Resected Locally Advanced Squamous Cell Carcinomas of the Head and Neck (HNSCC).

Kirtane K, Rodriguez CP.

Front Oncol. 2018 Dec 4;8:588. doi: 10.3389/fonc.2018.00588. eCollection 2018. Review.

3.

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.

Drilon A, Fu S, Patel MR, Fakih M, Wang D, Olszanski AJ, Morgensztern D, Liu SV, Cho BC, Bazhenova L, Rodriguez CP, Doebele RC, Wozniak A, Reckamp KL, Seery T, Nikolinakos P, Hu Z, Oliver JW, Trone D, McArthur K, Patel R, Multani PS, Ahn MJ.

Cancer Discov. 2019 Mar;9(3):384-395. doi: 10.1158/2159-8290.CD-18-0839. Epub 2018 Nov 28.

PMID:
30487236
4.

The mutational landscape of recurrent versus nonrecurrent human papillomavirus-related oropharyngeal cancer.

Harbison RA, Kubik M, Konnick EQ, Zhang Q, Lee SG, Park H, Zhang J, Carlson CS, Chen C, Schwartz SM, Rodriguez CP, Duvvuri U, Méndez E.

JCI Insight. 2018 Jul 26;3(14). pii: 99327. doi: 10.1172/jci.insight.99327. eCollection 2018 Jul 26.

5.

NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018.

Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Eisele DW, Fenton M, Foote RL, Gilbert J, Gillison ML, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Zhen W, Burns JL, Darlow SD.

J Natl Compr Canc Netw. 2018 May;16(5):479-490. doi: 10.6004/jnccn.2018.0026.

PMID:
29752322
6.

Racial disparity in oncologic and quality-of-life outcomes in patients with locally advanced head and neck squamous cell carcinomas enrolled in a randomized phase 2 trial.

Guerriero MK, Redman MW, Baker KK, Martins RG, Eaton K, Chow LQ, Santana-Davila R, Baik C, Goulart BH, Lee S, Rodriguez CP.

Cancer. 2018 Jul 1;124(13):2841-2849. doi: 10.1002/cncr.31407. Epub 2018 Apr 18.

PMID:
29669181
7.

A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma.

Méndez E, Rodriguez CP, Kao MC, Raju S, Diab A, Harbison RA, Konnick EQ, Mugundu GM, Santana-Davila R, Martins R, Futran ND, Chow LQM.

Clin Cancer Res. 2018 Jun 15;24(12):2740-2748. doi: 10.1158/1078-0432.CCR-17-3796. Epub 2018 Mar 13.

PMID:
29535125
8.

Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies.

Rodriguez CP, Martins RG, Baik C, Chow LQ, Santana-Davila R, Goulart BH, Lee S, Eaton KD.

Head Neck. 2018 Mar;40(3):584-589. doi: 10.1002/hed.25020. Epub 2017 Dec 28.

PMID:
29283469
9.

Immunotherapy for Head and Neck Cancer in the Era of Exponentially Increasing Health Care Expenditure.

Santana-Davila R, Rodriguez CP.

Oncologist. 2018 Feb;23(2):147-149. doi: 10.1634/theoncologist.2017-0527. Epub 2017 Nov 30. No abstract available.

10.

NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.

Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL Jr, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD.

J Natl Compr Canc Netw. 2017 Jun;15(6):761-770. doi: 10.6004/jnccn.2017.0101.

PMID:
28596256
11.

Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma.

Pellini Ferreira B, Redman M, Baker KK, Martins R, Eaton KD, Chow LQM, Baik CS, Goulart B, Lee SM, Santana-Davila R, Rodriguez CP.

Laryngoscope. 2017 Jul;127(7):1583-1588. doi: 10.1002/lary.26422. Epub 2016 Dec 1.

PMID:
27905113
12.

Persistent Dysphagia After Induction Chemotherapy in Patients with Esophageal Adenocarcinoma Predicts Poor Post-Operative Outcomes.

McNamara MJ, Adelstein DJ, Allende DS, Bodmann JW, Ives DI, Murthy SC, Raymond D, Raja S, Rodriguez CP, Sohal D, Stephans KL, Videtic GMM, Rybicki LA.

J Gastrointest Cancer. 2017 Jun;48(2):181-189. doi: 10.1007/s12029-016-9881-x.

PMID:
27734205
13.

Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: A single-institution experience.

Araki D, Redman MW, Martins R, Eaton K, Baik C, Chow L, Goulart B, Lee S, Santana-Davila R, Liao J, Parvathaneni U, Laramore G, Futran N, Mendez E, Bhrany A, Rodriguez CP.

Head Neck. 2016 Sep;38(9):1318-23. doi: 10.1002/hed.24437. Epub 2016 Apr 7.

PMID:
27061333
14.

The relationship between pathologic nodal disease and residual tumor viability after induction chemotherapy in patients with locally advanced esophageal adenocarcinoma receiving a tri-modality regimen.

McNamara MJ, Rybicki LA, Sohal D, Allende DS, Videtic GM, Rodriguez CP, Stephans KL, Murthy SC, Raja S, Raymond D, Ives DI, Bodmann JW, Adelstein DJ.

J Gastrointest Oncol. 2016 Apr;7(2):196-205. doi: 10.3978/j.issn.2078-6891.2015.097.

15.

Salivary Gland Malignancies.

Rodriguez CP, Parvathaneni U, Méndez E, Martins RG.

Hematol Oncol Clin North Am. 2015 Dec;29(6):1145-57. doi: 10.1016/j.hoc.2015.08.002. Epub 2015 Oct 17. Review.

PMID:
26568553
16.

Head and Neck Cancers, Version 1.2015.

Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Foote RL, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian N, Hughes M.

J Natl Compr Canc Netw. 2015 Jul;13(7):847-55; quiz 856.

17.

Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology.

Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Schuller DE, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 Oct;12(10):1454-87.

18.

A phase II trial of induction epirubicin, oxaliplatin, and fluorouracil, followed by surgery and postoperative concurrent cisplatin and fluorouracil chemoradiotherapy in patients with locoregionally advanced adenocarcinoma of the esophagus and gastroesophageal junction.

McNamara MJ, Adelstein DJ, Bodmann JW, Greskovich JF Jr, Ives DI, Mason DP, Murthy SC, Rice TW, Saxton JP, Sohal D, Stephans K, Rodriguez CP, Videtic GM, Rybicki LA.

J Thorac Oncol. 2014 Oct;9(10):1561-7. doi: 10.1097/JTO.0000000000000312.

19.

Genomic medicine and targeted therapy for solid tumors.

Stevens EA, Rodriguez CP.

J Surg Oncol. 2015 Jan;111(1):38-42. doi: 10.1002/jso.23699. Epub 2014 Jul 5. Review.

PMID:
25042935
20.

Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design.

Rodriguez CP, Adelstein DJ, Rybicki LA, Savvides P, Saxton JP, Koyfman SA, Greskovich JF, Yao M, Scharpf J, Lavertu P, Wood BG, Burkey BB, Lorenz RR, Rezaee RP, Zender CA, Ives DI.

Head Neck. 2015 Nov;37(11):1583-9. doi: 10.1002/hed.23794. Epub 2014 Oct 29.

PMID:
24909549
21.

Treatment implications of the new lung cancer staging system.

Rodriguez CP.

Cleve Clin J Med. 2012 May;79 Electronic Suppl 1:eS7-eS10. doi: 10.3949/ccjm.79.s2.02.

PMID:
22614969
22.

Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck.

Rodriguez CP, Adelstein DJ, Rybicki LA, Saxton JP, Lorenz RR, Wood BG, Scharpf J, Ives DI.

Head Neck. 2012 Nov;34(11):1517-23. doi: 10.1002/hed.21971. Epub 2011 Dec 16.

PMID:
22180262
23.

Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly.

Michal SA, Adelstein DJ, Rybicki LA, Rodriguez CP, Saxton JP, Wood BG, Scharpf J, Ives DI.

Head Neck. 2012 Aug;34(8):1147-52. doi: 10.1002/hed.21891. Epub 2011 Oct 22.

PMID:
22021098
24.

A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction.

Adelstein DJ, Rodriguez CP, Rybicki LA, Ives DI, Rice TW.

Invest New Drugs. 2012 Aug;30(4):1684-9. doi: 10.1007/s10637-011-9736-z. Epub 2011 Aug 24.

PMID:
21863238
25.

Intended single-modality management of T1 and T2 tonsillar carcinomas: retrospective comparison of radical tonsillectomy vs radiation from a single institution.

Lamarre ED, Seth R, Lorenz RR, Esclamado R, Adelstein DJ, Rodriguez CP, Saxton J, Scharpf J.

Am J Otolaryngol. 2012 Jan-Feb;33(1):98-103. doi: 10.1016/j.amjoto.2011.02.005. Epub 2011 Jun 22.

PMID:
21696857
26.

What is new in the management of salivary gland cancers?

Adelstein DJ, Rodriguez CP.

Curr Opin Oncol. 2011 May;23(3):249-53. doi: 10.1097/CCO.0b013e328344f59c. Review.

PMID:
21330920
27.

Esophagectomy for clinical high-grade dysplasia.

Rice TW, Murthy SC, Mason DP, Rybicki LA, Yerian LM, Dumot JA, Rodriguez CP, Blackstone EH.

Eur J Cardiothorac Surg. 2011 Jul;40(1):113-9. doi: 10.1016/j.ejcts.2010.10.020. Epub 2011 Jan 28.

PMID:
21277216
28.

Survival trends in head and neck cancer: opportunities for improving outcomes.

Rodriguez CP, Adelstein DJ.

Oncologist. 2010;15(9):921-3. doi: 10.1634/theoncologist.2010-0237. Epub 2010 Aug 26. No abstract available.

29.

Human papillomavirus: changing paradigms in oropharyngeal cancer.

Adelstein DJ, Rodriguez CP.

Curr Oncol Rep. 2010 Mar;12(2):115-20. doi: 10.1007/s11912-010-0084-5.

PMID:
20425596
30.

A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer.

Rodriguez CP, Adelstein DJ, Rice TW, Rybicki LA, Videtic GM, Saxton JP, Murthy SC, Mason DP, Ives DI.

J Thorac Oncol. 2010 Feb;5(2):229-35. doi: 10.1097/JTO.0b013e3181c5e334.

31.

Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction.

Adelstein DJ, Rice TW, Rybicki LA, Saxton JP, Videtic GM, Murthy SC, Mason DP, Rodriguez CP, Ives DI.

J Thorac Oncol. 2009 Oct;4(10):1264-9. doi: 10.1097/JTO.0b013e3181b26f8e.

32.

Does vocal cord fixation preclude nonsurgical management of laryngeal cancer?

Solares CA, Wood B, Rodriguez CP, Lorenz RR, Scharpf J, Saxton J, Rybicki LA, Strome M, Esclamado R, Lavertu P, Adelstein DJ.

Laryngoscope. 2009 Jun;119(6):1130-4. doi: 10.1002/lary.20225.

PMID:
19358250
33.

Clinical predictors of larynx preservation after multiagent concurrent chemoradiotherapy.

Rodriguez CP, Adelstein DJ, Rybicki LA, Saxton JP, Lorenz RR, Wood BG, Strome M, Esclamado RM, Lavertu P, Carroll MA.

Head Neck. 2008 Dec;30(12):1535-42. doi: 10.1002/hed.20902.

PMID:
18704968
34.

Current and emerging standards of concomitant chemoradiotherapy.

Adelstein DJ, Rodriguez CP.

Semin Oncol. 2008 Jun;35(3):211-20. doi: 10.1053/j.seminoncol.2008.03.004. Review.

PMID:
18544436
35.

Impact of socioeconomic status and distance from treatment center on survival in patients receiving remission induction therapy for newly diagnosed acute myeloid leukemia.

Rodriguez CP, Baz R, Jawde RA, Rybicki LA, Kalaycio ME, Advani A, Sobecks R, Sekeres MA.

Leuk Res. 2008 Mar;32(3):413-20. Epub 2007 Aug 28.

PMID:
17727945

Supplemental Content

Loading ...
Support Center